Amiodarone vs. Lidocaine in Ventricular Fibrillation

Shock-refractory ventricular fibrillation (VF) and pulseless ventricular tachycardia (pVT) are among the most time-critical situations you can encounter in emergency medicine. When sinus rhythm cannot be achieved after three defibrillation attempts and high-quality CPR, the question of pharmacological escalation inevitably arises. The two antiarrhythmics that play the greatest role in this context are amiodarone and lidocaine. Both substances are listed in the AHA guidelines as options for shock-refractory VF/pVT – but they differ fundamentally in their pharmacology, evidence base, and practical handling. This article compares both substances head-to-head and provides you with evidence-based guidance for clinical decision-making.

Pathophysiological Background: Why Antiarrhythmics in VF/pVT?

Ventricular fibrillation is a state of chaotic, uncoordinated electrical activity of the myocardium that is fatal without immediate defibrillation. Defibrillation remains the only causal therapy – no medication can terminate VF. Antiarrhythmics therefore pursue a different goal: they aim to lower the threshold for successful defibrillation, prevent recurrence of VF after successful cardioversion, and stabilize the myocardial substrate so that an organized rhythm can be maintained.

This point is crucial: antiarrhythmics do not replace defibrillation or high-quality CPR. They are an adjunctive tool that is used at the earliest after the third unsuccessful shock and the administration of epinephrine.

Amiodarone: Pharmacology and Dosing

Mechanism of Action

Amiodarone is a Class III antiarrhythmic according to the Vaughan-Williams classification but possesses properties of all four classes. It primarily blocks potassium channels, thereby prolonging the repolarization phase and the refractory period of the action potential. Additionally, it inhibits sodium channels (Class I), calcium channels (Class IV), and has a non-competitive antiadrenergic effect (Class II). This multi-class action explains its broad antiarrhythmic potency but also its complex side effect profile.

In the resuscitation context, intravenous administration is relevant. After bolus administration, amiodarone rapidly distributes into well-perfused organs – provided CPR delivers adequate cardiac output. The half-life after a single dose is approximately 4–10 hours; with chronic administration, it extends to weeks.

Dosing in the Resuscitation Algorithm

The AHA guidelines recommend the following approach:

• First dose: 300 mg amiodarone as an intravenous bolus (or intraosseous), undiluted or in 20 ml of 5% dextrose, after the third unsuccessful defibrillation attempt
• Second dose: 150 mg amiodarone as a bolus if VF/pVT persists
• Maximum resuscitation dose: 450 mg (300 mg + 150 mg)

After successful resuscitation, a maintenance infusion may be considered: 1 mg/min over 6 hours, followed by 0.5 mg/min over 18 hours (total dose in 24 hours: approximately 1050 mg). This post-ROSC infusion serves as recurrence prophylaxis.

Side Effects and Limitations

In the resuscitation context, side effects are secondary – survival takes priority. Nevertheless, you should be aware of the relevant adverse effects, especially for the post-ROSC phase:

• Hypotension: due to vasodilation and negative inotropy, especially with overly rapid infusion outside of resuscitation
• Bradycardia: can become relevant after ROSC and may require temporary pacing
• QT prolongation: risk of Torsades de Pointes, especially with hypokalemia or combination with other QT-prolonging agents
• Phlebitis: with peripheral venous administration; a central venous access or intraosseous access is preferred
• Long-term toxicity: thyroid, lung, liver, cornea – irrelevant in the acute resuscitation setting but significant when continuing therapy in the ICU

Lidocaine: Pharmacology and Dosing

Mechanism of Action

Lidocaine is a Class IB antiarrhythmic. It blocks voltage-gated sodium channels, preferentially binding to inactivated channels – that is, channels in depolarized, ischemic myocardium. This shortens the action potential duration and the refractory period, suppresses abnormal automaticity, and raises the fibrillation threshold.

Compared to amiodarone, lidocaine acts significantly more selectively: it primarily affects ischemic tissue and has fewer hemodynamic side effects. The half-life is 1.5–2 hours, resulting in more controllable pharmacodynamics.

Dosing in the Resuscitation Algorithm

The AHA guidelines list lidocaine as an alternative to amiodarone for shock-refractory VF/pVT:

• First dose: 1–1.5 mg/kg body weight intravenously as a bolus
• Subsequent doses: 0.5–0.75 mg/kg every 5–10 minutes
• Maximum resuscitation dose: 3 mg/kg

For an 80 kg patient, this means: initial dose 80–120 mg, subsequent doses 40–60 mg, maximum 240 mg.

After ROSC, a maintenance infusion of 1–4 mg/min may be considered. The dose should be reduced in patients with impaired hepatic function, heart failure, and in elderly patients, as lidocaine is hepatically metabolized.

Side Effects and Limitations

• CNS toxicity: paresthesias, confusion, seizures – dose-dependent, rare in the resuscitation context but relevant after ROSC during maintenance infusion
• Bradycardia and AV block: less frequent than with amiodarone but possible
• Negative inotropy: mild, but should be considered in severely impaired LV function
• Proarrhythmia: described in isolated cases, overall less frequent than with Class III agents

Evidence: Head-to-Head Comparison

The ALIVE Study

The most important randomized study directly comparing amiodarone and lidocaine in out-of-hospital cardiac arrest is the ALIVE study (Amiodarone versus Lidocaine in prehospital Ventricular Fibrillation Evaluation). In this double-blind, randomized study, patients with shock-refractory VF after at least three defibrillation attempts were treated with either amiodarone (5 mg/kg) or lidocaine (1.5 mg/kg).

The result: amiodarone showed a significantly higher rate of hospital admission compared to lidocaine (22.8% vs. 12.0%). This survival advantage up to hospital admission was statistically significant and clinically relevant.

But – and this is the key point: The study was not powered to show a difference in survival to hospital discharge or neurological outcome. The rate of discharge with good neurological outcome did not differ significantly.

The ALPS Study

The ALPS study (Amiodarone, Lidocaine, or Placebo Study) investigated amiodarone vs. lidocaine vs. placebo in a three-arm design for out-of-hospital shock-refractory VF/pVT. It is the largest and methodologically most rigorous study on this question to date.

The results:

• Primary endpoint (survival to hospital discharge): No significant difference between amiodarone (24.4%), lidocaine (23.7%), and placebo (21.0%)
• Secondary endpoint (good neurological outcome): Also no significant difference between the three groups
• Subgroup analysis: In bystander-witnessed arrest, there was a trend favoring amiodarone over placebo

The ALPS study fundamentally changed the perspective on antiarrhythmics in VF/pVT: neither amiodarone nor lidocaine demonstrably improves survival to hospital discharge or neurological outcome compared to placebo. This led to the AHA guidelines downgrading the recommendation class for both substances.

Summary of Evidence

Parameter	Amiodarone	Lidocaine
Class (Vaughan-Williams)	III (with Class I, II, IV properties)	IB
Initial resuscitation dose	300 mg IV/IO bolus	1–1.5 mg/kg IV/IO
Repeat dose	150 mg	0.5–0.75 mg/kg
Maximum dose	450 mg	3 mg/kg
Survival to hospital admission	Advantage (ALIVE study)	Inferior vs. amiodarone
Survival to discharge	No advantage vs. placebo	No advantage vs. placebo
Neurological outcome	No advantage vs. placebo	No advantage vs. placebo
AHA recommendation class	IIb	IIb
Hemodynamic effects	Greater hypotension	Minimal
Controllability	Low (long half-life)	Good (short half-life)

Current AHA Recommendation

The AHA guidelines give both substances a Class IIb recommendation (Level of Evidence B) for shock-refractory VF/pVT. This means: administration may be considered – but it is not a strong recommendation. In the ACLS algorithm, use is outlined as follows:

1. First shock → immediately resume CPR (2 minutes)
2. Rhythm analysis → if still VF/pVT: second shock → CPR
3. Rhythm analysis → if still VF/pVT: Epinephrine 1 mg IV/IO → third shock → CPR
4. Rhythm analysis → if still VF/pVT: Amiodarone 300 mg OR Lidocaine 1–1.5 mg/kg → fourth shock → CPR
5. Epinephrine 1 mg repeated every 3–5 minutes
6. If persistent: Amiodarone 150 mg or Lidocaine 0.5–0.75 mg/kg as a repeat dose

Crucially: the guidelines present amiodarone and lidocaine as equivalent alternatives. There is no explicit preference for one substance over the other.

Clinical Decision Guide: When to Use Which Agent?

Despite the formally equivalent recommendation, there are clinical scenarios in which one of the two substances may offer advantages:

Arguments for Amiodarone

• Standard medication in most EMS systems and emergency departments – team familiarity is a safety factor
• Broader spectrum of action due to multi-class effect
• Subgroup analysis of the ALPS study suggests a possible advantage in bystander-witnessed cardiac arrest
• No dose adjustment required for impaired hepatic or renal function in the resuscitation context

Arguments for Lidocaine

• Better hemodynamic tolerability – less hypotension after ROSC
• Shorter half-life – better controllability, especially when a drug switch becomes necessary
• Lower risk of QT prolongation – relevant when the cause of VF is already QT prolongation (e.g., drug-induced Torsades de Pointes)
• Preferential action on ischemic myocardium – theoretical advantage in VF in the context of acute myocardial infarction
• Availability: In some settings (e.g., anesthesia), lidocaine is already stocked

Special Situation: Torsades de Pointes

In polymorphic VF in the context of QT prolongation (Torsades de Pointes), amiodarone is contraindicated as it further prolongs the QT interval. Magnesium sulfate (1–2 g IV over 1–2 minutes) is the first-line therapy here. Lidocaine may be considered as an antiarrhythmic in this context, as it does not prolong the QT interval and may even shorten it.

Special Situation: Cocaine-Associated VF

In cocaine-induced VF, lidocaine is preferred by some experts because cocaine itself possesses sodium channel-blocking properties, and the additional sodium channel blockade from amiodarone could exacerbate the problem. However, the evidence for this is limited and stems predominantly from case reports and animal studies.

Don't Forget Reversible Causes

Regardless of the choice of antiarrhythmic, the following applies: in shock-refractory VF/pVT, you must systematically search for reversible causes. The 5 H's and 5 T's mnemonic structures this search:

5 H's:

• Hypovolemia
• Hypoxia
• Hypothermia
• Hypo-/Hyperkalemia (and other electrolyte disturbances)
• Hydrogen ions (acidosis)

5 T's:

• Thrombosis (coronary → STEMI)
• Thrombosis (pulmonary → pulmonary embolism)
• Tamponade (cardiac tamponade)
• Tension (tension pneumothorax)
• Toxins (poisoning/intoxication)

No antiarrhythmic can compensate for an untreated cause. Persistent hyperkalemia, an undrained pericardial tamponade, or a massive pulmonary embolism require cause-directed interventions – in parallel with CPR.

Summary for Clinical Practice

• Amiodarone and lidocaine are equivalent options for shock-refractory VF/pVT (AHA Class IIb)
• Neither medication demonstrably improves long-term neurological outcome
• The core therapy remains: high-quality CPR, early defibrillation, epinephrine every 3–5 minutes, systematic search for reversible causes
• Amiodarone is the more commonly used medication and the standard choice in most algorithms
• Lidocaine is a valid alternative, especially in Torsades de Pointes, hemodynamic instability after ROSC, or when QT prolongation is suspected as the cause
• Know both substances, their dosing, and contraindications – there is no time to look things up during resuscitation

Hands-On Training

The safe use of antiarrhythmics in ventricular fibrillation requires more than theoretical knowledge. What matters is seamless integration into the resuscitation algorithm, correct dosing under time pressure, and structured team communication. In the ACLS courses offered by Simulation Tirol, you train exactly these scenarios in realistic simulations – including the decision between amiodarone and lidocaine, the management of reversible causes, and post-ROSC care. The AHA-certified course format ensures that you not only know the current guidelines but can apply them confidently under pressure.